Literature DB >> 12450219

Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology.

Zhongmin Xiang1, Lap Ho, Shrishailam Yemul, Zhong Zhao, Wein Qing, Patrick Pompl, Kevin Kelley, Anju Dang, Weiping Qing, David Teplow, Giulio Maria Pasinetti.   

Abstract

Several epidemiologic studies have reported that cyclooxygenase (COX) inhibitors prevent/delay the onset of Alzheimer's disease (AD). Recent experimental studies suggest that these compounds can also diminish amyloid-beta (Abeta) neuropathology in rodent models of AD. To explore the relationship of COX expression to Abeta neuropathology, we crossed mice expressing both mutant amyloid precursor protein [K670N/M671L (APP(swe)] and mutant PS1 (A246E) with mice expressing human COX-2 selectively in neurons. We show here that human COX-2 expression in APP(swe)/PS1/COX-2 mice induces potentiation of brain parenchymal amyloid plaque formation and a greater than twofold increase in prostaglandin E2 production, at 24 months of age. This increased amyloid plaque formation coincided with a preferential elevation of Abeta1-40 and Abeta1-42 with no change in total amyloid precursor protein (APP) expression/content in the brain. Collectively these data suggest that COX-2 influences APP processing and promotes amyloidosis in the brain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450219      PMCID: PMC5977525          DOI: 10.3727/000000002783992352

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  21 in total

1.  Profiling of amyloid beta peptide variants using SELDI Protein Chip arrays.

Authors:  H Davies; L Lomas; B Austen
Journal:  Biotechniques       Date:  1999-12       Impact factor: 1.993

Review 2.  Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders.

Authors:  A Yermakova; M K O'Banion
Journal:  Curr Pharm Des       Date:  2000-11       Impact factor: 3.116

3.  Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor.

Authors:  C Haass; A Y Hung; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1994-07-01       Impact factor: 5.157

4.  Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs.

Authors:  K Yasojima; C Schwab; E G McGeer; P L McGeer
Journal:  Brain Res       Date:  1999-06-05       Impact factor: 3.252

5.  Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease.

Authors:  L Ho; D Purohit; V Haroutunian; J D Luterman; F Willis; J Naslund; J D Buxbaum; R C Mohs; P S Aisen; G M Pasinetti
Journal:  Arch Neurol       Date:  2001-03

6.  Risk of Alzheimer's disease and duration of NSAID use.

Authors:  W F Stewart; C Kawas; M Corrada; E J Metter
Journal:  Neurology       Date:  1997-03       Impact factor: 9.910

7.  Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2.

Authors:  Lauren Spielman; David Winger; Lap Ho; Paul S Aisen; Esther Shohami; Giulio Maria Pasinetti
Journal:  Acta Neuropathol       Date:  2001-11-24       Impact factor: 17.088

Review 8.  Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.

Authors:  T E Golde; C B Eckman; S G Younkin
Journal:  Biochim Biophys Acta       Date:  2000-07-26

9.  Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease.

Authors:  L Ho; C Pieroni; D Winger; D P Purohit; P S Aisen; G M Pasinetti
Journal:  J Neurosci Res       Date:  1999-08-01       Impact factor: 4.164

10.  beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain.

Authors:  H Jiang; D Burdick; C G Glabe; C W Cotman; A J Tenner
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

View more
  43 in total

1.  The cyclooxygenase site, but not the peroxidase site of cyclooxygenase-2 is required for neurotoxicity in hypoxic and ischemic injury.

Authors:  Wenjin Li; Shasha Wu; Muzamil Ahmad; Jianfei Jiang; Hao Liu; Tetsuya Nagayama; Marie E Rose; Vladimir A Tyurin; Yulia Y Tyurina; Grigory G Borisenko; Natalia Belikova; Jun Chen; Valerian E Kagan; Steven H Graham
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

Review 2.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

3.  CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.

Authors:  Sungho Lee; Nicholas H Varvel; Megan E Konerth; Guixiang Xu; Astrid E Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

Review 4.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 5.  Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?

Authors:  Lap Ho; Weiping Qin; Breton S Stetka; Giulio M Pasinetti
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42.

Authors:  Olivier Boutaud; Thomas J Montine; Lei Chang; William L Klein; John A Oates
Journal:  J Neurochem       Date:  2006-01-12       Impact factor: 5.372

7.  Microsomal prostaglandin E synthase-2: cellular distribution and expression in Alzheimer's disease.

Authors:  Uzma Chaudhry; Hean Zhuang; Sylvain Doré
Journal:  Exp Neurol       Date:  2009-08-05       Impact factor: 5.330

8.  Thinking outside the box about COX-1 in Alzheimer's disease.

Authors:  Sally A Frautschy
Journal:  Neurobiol Dis       Date:  2010-03-02       Impact factor: 5.996

Review 9.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

10.  Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease.

Authors:  Syaun Sung; Hengxuan Yang; Kunihiro Uryu; Edward B Lee; Lei Zhao; Diana Shineman; John Q Trojanowski; Virginia M-Y Lee; Domenico Praticò
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.